Literature DB >> 24170210

EGFR expression in pancreatic adenocarcinoma. Relationship to tumour morphology and cell adhesion proteins.

Adriana Handra-Luca1, Pascal Hammel, Alain Sauvanet, Claude Lesty, Philippe Ruszniewski, Anne Couvelard.   

Abstract

AIMS: We aimed to study epidermal growth factor receptor (EGFR) expression in surgically resected pancreatic ductal adenocarcinomas (PDACs) by immunohistochemistry and their relationship to clinicopathological features, cell proliferation and cell adhesion protein expression.
METHODS: A total of 99 PDACs were analysed on tissue microarrays for EGFR, E-cadherin and β-catenin expression patterns in tumour cells. The percentage of cells expressing the three proteins (membrane, cytoplasm or nuclear pattern) and of Ki67-positive tumour cells was assessed. Tumour protein expression was studied with regard to clinicomorphological features, Ki67 index and for postsurgical survival.
RESULTS: Membrane tumour EGFR correlated with histological poor differentiation (dedifferentiation), increased number of mitoses and severe tumour cell atypia (pleiomorphism) as well as with aberrant adhesion protein expression such as nuclear β-catenin and cytoplasmic E-cadherin. Cytoplasmic tumour E-cadherin correlated with an increased Ki67-positive tumour cell component, whereas nuclear E-cadherin correlated with a shorter postsurgical overall survival, as well as with tumour necrosis and an abundant clear cell component.
CONCLUSIONS: In conclusion, the results of our study suggest a complex role for EGFR in PDAC carcinogenesis, tumour expression of this protein being associated with tumour dedifferentiation, mitotic activity or pleiomorphism, as well as with aberrant tumour cell adhesion protein expression.

Entities:  

Keywords:  Carcinoma; Immunohistochemistry; Pancreas

Mesh:

Substances:

Year:  2013        PMID: 24170210     DOI: 10.1136/jclinpath-2013-201662

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  EGFR expression in pancreatic intraepithelial neoplasia and ductal adenocarcinoma.

Authors:  Seok Ju Park; Mi Jin Gu; Dong Shik Lee; Sung Soo Yun; Hong Jin Kim; Joon Hyuk Choi
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

2.  Association between EGFR polymorphisms and the risk of lung cancer.

Authors:  Changjiang Liu; Xiaorong Xu; Yufa Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

3.  Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma.

Authors:  Huanwen Wu; Liang Zhu; Hui Zhang; Xiaohua Shi; Li Zhang; Wenze Wang; Huadan Xue; Zhiyong Liang
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

4.  Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma.

Authors:  Li Wang; Huanwen Wu; Lili Wang; Junliang Lu; Huanli Duan; Xuguang Liu; Zhiyong Liang
Journal:  Diagn Pathol       Date:  2016-07-08       Impact factor: 2.644

5.  Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery.

Authors:  Susanna W L de Geus; Leonora S F Boogerd; Rutger-Jan Swijnenburg; J Sven D Mieog; Willemieke S F J Tummers; Hendrica A J M Prevoo; Cornelis F M Sier; Hans Morreau; Bert A Bonsing; Cornelis J H van de Velde; Alexander L Vahrmeijer; Peter J K Kuppen
Journal:  Mol Imaging Biol       Date:  2016-12       Impact factor: 3.488

6.  E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors.

Authors:  Eike Burandt; Felix Lübbersmeyer; Natalia Gorbokon; Franziska Büscheck; Andreas M Luebke; Anne Menz; Martina Kluth; Claudia Hube-Magg; Andrea Hinsch; Doris Höflmayer; Sören Weidemann; Christoph Fraune; Katharina Möller; Frank Jacobsen; Patrick Lebok; Till Sebastian Clauditz; Guido Sauter; Ronald Simon; Ria Uhlig; Waldemar Wilczak; Stefan Steurer; Sarah Minner; Rainer Krech; David Dum; Till Krech; Andreas Holger Marx; Christian Bernreuther
Journal:  Biomark Res       Date:  2021-06-05

7.  Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma.

Authors:  Willemieke S Tummers; Arantza Farina-Sarasqueta; Martin C Boonstra; Hendrica A Prevoo; Cornelis F Sier; Jan S Mieog; Johannes Morreau; Casper H van Eijck; Peter J Kuppen; Cornelis J van de Velde; Bert A Bonsing; Alexander L Vahrmeijer; Rutger-Jan Swijnenburg
Journal:  Oncotarget       Date:  2017-05-26

8.  Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.

Authors:  F A Vuijk; L D A N de Muynck; L C Franken; O R Busch; J W Wilmink; M G Besselink; B A Bonsing; S S Bhairosingh; P J K Kuppen; J S D Mieog; C F M Sier; A L Vahrmeijer; J Verheij; A Fariňa-Sarasqueta; R J Swijnenburg
Journal:  Sci Rep       Date:  2020-10-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.